A new drug has finally been approved. A launch date is set. A new dosage form is added. The package size changes. The product appears on the NHI price list. Every time a product reaches the market, there is a moment when a company wants to let medical institutions and healthcare professionals know. The single sheet handed out at that moment is what this chapter calls a notice document. It looks light, almost like an administrative memo. Yet the Guide sees a trap hidden in that lightness. The label "notice" can become a side door through which efficacy and safety claims — which would otherwise be tightly governed — slip in dressed up as a mere announcement.
What a notice document conveys is, in principle, the fact that something has happened. The notification of an event — approved, launched, listed — is the body of the document. It is not a place to say how well the drug works or how safe it is. The moment you begin to say that, the character of the document changes.
01What a notice document is
A notice document announces milestones concerning one's own prescription drug to medical institutions and healthcare professionals. The events it typically covers include:
- obtaining a new approval
- announcing a new launch (start of sales)
- an additional approval for indications or dosage and administration
- listing on the NHI drug price standard
- addition of a dosage form
- a change in package unit
Its audience is the medical institution, not the general public. This is the decisive difference from disease-explanation materials and patient-facing materials. Assuming readers who are specialists in prescribing and dispensing, it conveys the necessary milestone concisely. That is its proper role.
Press releases are not included
Even though it is also a kind of "announcement," a press release aimed at the media, investors, or society at large is not part of the notice document covered by this chapter. The two differ in both recipient and purpose. A press release is a disclosure of corporate activity; it is not a material that directs medical institutions in how to use a particular drug. Treating the text of a press release as something to be transplanted directly into a notice for medical institutions mistakes the reach of this chapter.
02Why an "announcement" still needs brakes
The foreword positions materials such as product information summaries as a complement to the electronic package insert. The original text is the approved content, and a material cannot exceed that approved scope by a single character. The notice document, too, lives under this constitution. Notifying the fact that "it has been approved" is itself within the approved scope, so little goes wrong. But the instant you step further into "approved, and this is how well it works," it becomes an efficacy claim and enters the far heavier territory of approved scope, supporting data, and balance with safety.
Another implication of the foreword also bites here: the absence of an item in the manual does not mean freedom. The notice document is short and few rules are written for it. But that is not a "blank space where anything may be written." Rather, the rules are few precisely because what may be written is confined to the notification of facts.
The duty to "not mislead, and to convey accurately" is at work as well. Not writing falsehoods and not letting a false image form are separate duties. If a launch announcement carries a figure that evokes efficacy, or a line that suggests superiority over a competitor, then even with no lie anywhere in the text, the reader forms the image "this drug works especially well." The Guide is wary of the notice document becoming the entrance to that kind of impression-shaping.
03Carry concrete results, and it stops being a notice
This is the heart of the chapter. If you wish to place concrete results on a drug's efficacy or safety into a notice document, it is no longer a mere announcement. It must be prepared as a specific-item product information summary. The title may remain "notice," but the moment the content begins to speak of clinical data, the governing discipline switches over entirely.
| Aspect | A pure notice document | A document carrying concrete results |
|---|---|---|
| Content | Notification of facts: approval, launch, listing, etc. | Concrete efficacy and safety data |
| Positioning | An announcement material | Treated as a specific-item product information summary |
| Discipline owed | The scope needed for an announcement | Chapter 1 basic considerations + the full Chapter 3 specific-item rules |
| Typical required elements | Accurate statement of fact | Warnings/contraindications, indications and dosage, balance with safety, sources, date of preparation or revision, etc. |
Why is this switch required? Showing concrete results means handing over information that directly affects the reader's prescribing decision. That brings with it the whole verifiability framework a product information summary carries: the quality of the evidence (a confirmatory analysis, or an exploratory post hoc or subgroup result), the symmetric disclosure of efficacy and safety, the clear citation of sources, and the date of preparation or revision that preserves the version. The announcement format does not exempt any of these. This rule blocks the escape into light treatment under the banner of "just a notice."
Adding a single graph of the primary endpoint result to a "launch notice" — this looks like light decoration, but it is already the posting of concrete results. At that moment the document falls under the discipline of a specific-item product information summary. You now have to show safety at equal or greater prominence, attach the source, and address warnings and contraindications. "It's only one graph" does not hold.
Where is the boundary
The test is simple. Does the statement become material that lets the reader "evaluate" the drug's efficacy or safety? "Launching on the Xth" stays a notification of fact. "Met its primary endpoint in trial XX and is now launching" shows the achievement as a result and steers toward an impression of superiority. The latter is no longer an announcement. When in doubt, ask whether the document still stands as a "notice" with that sentence removed. If it cannot be removed, it is not an announcement but a claim.
04Do not import advertising catchphrases or the "features" section
There is another clear prohibition. Catchphrases used in journal advertisements, and the wording of the features section of a comprehensive product information summary, must not be diverted into a notice document.
This prohibition has its reasons. An advertising catchphrase is promotional language honed to catch attention within limited space. The features section is the very place the Guide itself names as "most prone to exaggeration," and where it strictly imposes the balance of efficacy and safety and the attachment of supporting data. Carry such strongly promotional expressions into a thinly-regulated notice document, and the promotion walks off on its own — without the brakes that should accompany it (citation of the basis, symmetry with safety, the page reference). The result is, in substance, an advertisement borrowing the guise of an announcement.
Put differently, the notice document is not a place to borrow the "feels effective" language honed in other materials. State facts in the language of facts. If you want to speak of efficacy, do so under the discipline that suits it — a specific-item product information summary — bearing the basis and the safety with it. Keeping the two unmixed is the consistent stance of this chapter.
05What this chapter embodies
The rules for the notice document are short. But within that brevity is concentrated the whole design philosophy of the Guide. A material's character is decided by its content, not by the name on its cover. Title it "notice" all you like — once it begins to speak of concrete efficacy and safety results, it is a specific-item product information summary and owes the corresponding discipline. The Guide closes, one by one, the routes by which lightening the label lets one escape the rules.
Here is the most practical expression of the foreword's principle that "what is outside the rules is not free." Even on a plain single sheet called a notice document, the higher norms run through: the principle of complementarity, the prohibition on misleading, and the securing of verifiability.
A notice document is an announcement material for accurately telling medical institutions about factual milestones — approval, launch, listing, addition of a dosage form, change of package. Press releases are not included.
If you want to carry concrete results on your drug's efficacy or safety, the document is no longer an announcement: it must be built as a specific-item product information summary, satisfying the Chapter 1 basic considerations and the full set of Chapter 3 rules. Diverting catchphrases from journal advertisements or the wording of the features section is likewise not allowed.
In short, this chapter does not permit carrying a heavy claim under a light label. Facts as facts; efficacy under the discipline that suits efficacy — keeping that line is the right way to build a notice document.